Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 14/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | FABP3 | P05413 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22852994 | 1.00 | DHODH (0.56) | DHODHMEN1KMT2AMAPK1FABP3 | |
| SCHEMBL30294653 | 0.92 | P2RY4 (0.56) | DHODHMEN1KMT2AMAPK1FABP3 | |
| SCHEMBL22853383 | 0.92 | P2RY4 (0.56) | DHODHMEN1KMT2AMAPK1FABP3 | |
| SCHEMBL22852993 | 0.85 | KDM4E (0.54) | DHODHMEN1KMT2AFABP3FABP4 | |
| SCHEMBL30294397 | 0.85 | KDM4E (0.54) | DHODHMEN1KMT2AFABP3FABP4 | |
| SCHEMBL22853121 | 0.85 | IDO1 (0.48) | DHODHMEN1KMT2AMAPK1FABP3 | |
| SCHEMBL30294377 | 0.85 | IDO1 (0.48) | DHODHMEN1KMT2AMAPK1FABP3 | |
| SCHEMBL22853331 | 0.85 | AKR1C3 (0.59) | MEN1KMT2AMAPK1FABP3FABP4 | |
| SCHEMBL30294672 | 0.85 | AKR1C3 (0.59) | MEN1KMT2AMAPK1FABP3FABP4 | |
| SCHEMBL22853346 | 0.84 | IDO1 (0.50) | DHODHMEN1KMT2AMAPK1FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | DHODH 1951/4885MEN1 1826/4885KMT2A 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.